These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 38157850)
21. The Tumorigenic Potential of Human Pluripotent Stem Cells. Lezmi E; Benvenisty N Stem Cells Transl Med; 2022 Aug; 11(8):791-796. PubMed ID: 35679163 [TBL] [Abstract][Full Text] [Related]
22. The Genomic Health of Human Pluripotent Stem Cells: Genomic Instability and the Consequences on Nuclear Organization. Henry MP; Hawkins JR; Boyle J; Bridger JM Front Genet; 2018; 9():623. PubMed ID: 30719030 [TBL] [Abstract][Full Text] [Related]
23. A Method to Map Gene Essentiality of Human Pluripotent Stem Cells by Genome-Scale CRISPR Screens with Inducible Cas9. Mair B; Aregger M; Tong AHY; Chan KSK; Moffat J Methods Mol Biol; 2022; 2377():1-27. PubMed ID: 34709608 [TBL] [Abstract][Full Text] [Related]
24. Engineered peptide modified hydrogel platform for propagation of human pluripotent stem cells. Richardson T; Wiegand C; Adisa F; Ravikumar K; Candiello J; Kumta P; Banerjee I Acta Biomater; 2020 Sep; 113():228-239. PubMed ID: 32603868 [TBL] [Abstract][Full Text] [Related]
25. Chemical Reversion of Conventional Human Pluripotent Stem Cells to a Naïve-like State with Improved Multilineage Differentiation Potency. Park TS; Zimmerlin L; Evans-Moses R; Zambidis ET J Vis Exp; 2018 Jun; (136):. PubMed ID: 29939183 [TBL] [Abstract][Full Text] [Related]
26. Modeling the selective growth advantage of genetically variant human pluripotent stem cells to identify opportunities for manufacturing process control. Beltran-Rendon C; Price CJ; Glen K; Stacey A; Barbaric I; Thomas RJ Cytotherapy; 2024 Apr; 26(4):383-392. PubMed ID: 38349312 [TBL] [Abstract][Full Text] [Related]
27. Engineered hematopoietic and immune cells derived from human pluripotent stem cells. Chang Y; Hummel SN; Jung J; Jin G; Deng Q; Bao X Exp Hematol; 2023 Nov; 127():14-27. PubMed ID: 37611730 [TBL] [Abstract][Full Text] [Related]
28. Revised "hPSC-Sac Method" for Simple and Efficient Differentiation of Human Pluripotent Stem Cells to Hematopoietic Progenitor Cells. Yuzuriha A; Eto K Methods Mol Biol; 2022; 2454():411-422. PubMed ID: 34724185 [TBL] [Abstract][Full Text] [Related]
29. Trisomy 12 compromises the mesendodermal differentiation propensity of human pluripotent stem cells. Yanagihara K; Hayashi Y; Liu Y; Yamaguchi T; Hemmi Y; Kokunugi M; Yamada KU; Fukumoto K; Suga M; Terada S; Nikawa H; Kawabata K; Furue M In Vitro Cell Dev Biol Anim; 2024 May; 60(5):521-534. PubMed ID: 38169039 [TBL] [Abstract][Full Text] [Related]
30. Tissue of Origin, but Not XCI State, Influences Germ Cell Differentiation from Human Pluripotent Stem Cells. Chang YW; Overeem AW; Roelse CM; Fan X; Freund C; Chuva de Sousa Lopes SM Cells; 2021 Sep; 10(9):. PubMed ID: 34572048 [TBL] [Abstract][Full Text] [Related]
31. A massive suspension culture system with metabolic purification for human pluripotent stem cell-derived cardiomyocytes. Hemmi N; Tohyama S; Nakajima K; Kanazawa H; Suzuki T; Hattori F; Seki T; Kishino Y; Hirano A; Okada M; Tabei R; Ohno R; Fujita C; Haruna T; Yuasa S; Sano M; Fujita J; Fukuda K Stem Cells Transl Med; 2014 Dec; 3(12):1473-83. PubMed ID: 25355733 [TBL] [Abstract][Full Text] [Related]
32. The tumorigenic potential of pluripotent stem cells: What can we do to minimize it? Peterson SE; Garitaonandia I; Loring JF Bioessays; 2016 Jul; 38 Suppl 1():S86-95. PubMed ID: 27417126 [TBL] [Abstract][Full Text] [Related]
33. The consequences of recurrent genetic and epigenetic variants in human pluripotent stem cells. Andrews PW; Barbaric I; Benvenisty N; Draper JS; Ludwig T; Merkle FT; Sato Y; Spits C; Stacey GN; Wang H; Pera MF Cell Stem Cell; 2022 Dec; 29(12):1624-1636. PubMed ID: 36459966 [TBL] [Abstract][Full Text] [Related]
34. One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells. Asplund A; Pradip A; van Giezen M; Aspegren A; Choukair H; Rehnström M; Jacobsson S; Ghosheh N; El Hajjam D; Holmgren S; Larsson S; Benecke J; Butron M; Wigander A; Noaksson K; Sartipy P; Björquist P; Edsbagge J; Küppers-Munther B Stem Cell Rev Rep; 2016 Feb; 12(1):90-104. PubMed ID: 26385115 [TBL] [Abstract][Full Text] [Related]
35. Application of human pluripotent stem cells and pluripotent stem cell-derived cellular models for assessing drug toxicity. Apáti Á; Varga N; Berecz T; Erdei Z; Homolya L; Sarkadi B Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):61-75. PubMed ID: 30526128 [No Abstract] [Full Text] [Related]
36. X chromosome inactivation in human pluripotent stem cells as a model for human development: back to the drawing board? Geens M; Chuva De Sousa Lopes SM Hum Reprod Update; 2017 Sep; 23(5):520-532. PubMed ID: 28582519 [TBL] [Abstract][Full Text] [Related]
37. MSX2 Initiates and Accelerates Mesenchymal Stem/Stromal Cell Specification of hPSCs by Regulating TWIST1 and PRAME. Zhang L; Wang H; Liu C; Wu Q; Su P; Wu D; Guo J; Zhou W; Xu Y; Shi L; Zhou J Stem Cell Reports; 2018 Aug; 11(2):497-513. PubMed ID: 30033084 [TBL] [Abstract][Full Text] [Related]
38. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening. Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632 [TBL] [Abstract][Full Text] [Related]
39. Culture conditions affect cardiac differentiation potential of human pluripotent stem cells. Ojala M; Rajala K; Pekkanen-Mattila M; Miettinen M; Huhtala H; Aalto-Setälä K PLoS One; 2012; 7(10):e48659. PubMed ID: 23119085 [TBL] [Abstract][Full Text] [Related]